Expired activity
Please go to the PowerPak homepage and select a course.

Fungal Frontiers: Expert Decision Making in Medical Mycology

This activity is jointly provided by Postgraduate Institute for Medicine (www.pimed.com); University of Nebraska Medical Center, Center for Continuing Education; Terranova Medica, LLC; and the Mycoses Study Group Educational and Research Consortium.

This activity is supported by independent educational grants from Astellas; Merck & Co, Inc.; and Gilead Sciences Europe, Ltd.

Release date

August 1, 2018

Expiration date

July 31, 2019

Estimated time to complete activity

2 hours



fee information

There is no fee for this educational activity.

Target Audience

This activity is intended for pharmacists engaged in the care of patients with invasive fungal diseases (IFD).


The goal of this activity is to support clinical pharmacists in their efforts to address challenging scenarios in the management of invasive fungal disease and improve patient outcomes.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Define the role of emerging diagnostics in the management of invasive fungal disease (IFD)
  • Discuss epidemiologic/resistance trends having an impact on IFD management
  • Choose appropriate antifungal therapeutics, with an eye toward pharmacologic optimization


Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, CMQ
Professor of Medicine and Epidemiology
Director, Laboratory of Mycology Research
University of Texas Medical School at Houston 
Houston, Texas

Melissa D. Johnson, PharmD, MHS, AAHIVP
Liaison Clinical Pharmacist for Duke Antimicrobial Stewardship Outreach Network
Associate Professor of Medicine 
Division of infectious Diseases
Duke University Medical Center
Durham, North Carolina

Jose A. Vazquez, MD, FACP, FIDSA
Chief, Division of Infectious Diseases and Professor of Medicine
Medical College of Georgia 
Augusta University
Augusta, Georgia


Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, CMQ  has:
Research support from Astellas; Cidara; Pfizer, Inc.; Scynexis
Advisory board fees from Cidara; Merck & Co., Inc.; Pfizer; Scynexis 
Consultant fees from Astellas; Bayer; Aradigm
Speakers bureau honorarium from Gilead; Merck & Co., Inc.; Pfizer, Inc.

Melissa D. Johnson, PHARMD, MHS, AAHIVP  has:
Research support from Charles River Laboratories; Merck & Co., Inc.
Royalty fees from UpToDate

Jose A. Vazquez, MD, FACP, FIDSA  has:
Research support from Astellas
Advisory board fees from Cidara
Consultant fees from Cidara; T2 Biosystems

Planners and Managers

The PIM planners and managers have nothing to disclose. The Terranova Medica, LLC planner, Lisa Tushla, PHD, (ASCP),  has nothing to disclose. The University of Nebraska Medical Center, Center for Continuing Education planner has nothing to disclose. The Mycoses Study Group Educational and Research Consortium planner, Peter Pappas, MD has disclosed he has consultant fees from Amplyx, Inc.; Cidara Therapeutics, Inc.; Scynexis; and Vical as well as research/investigator funding from Astellas; Cidara Therapeutics, Inc.; IMMY; T2 Biosystems; Scynexis; and Vical.


Joint Accreditation Statement
Jointly Accredited ProviderIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine; the University of Nebraska Medical Center, Center for Continuing Education; Terranova Medica, LLC; and the Mycoses Study Group Educational and Research Consortium.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 2 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA4008162-9999-18-206-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education
Interprofessional Continuing EducationThis activity was planned by and for the healthcare team, and learners will receive 2 Interprofessional Continuing Education (IPCE) credit for learning and change.


During the period August 1, 2018 through July 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your Statement of Participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number.  All Credit information will be uploaded into CPE monitor within 30 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5